Vikrant Shrotriya, Novo Nordisk India MD responds to questions on future pricing, generics competition post patent expiry in March, Indian-specific pricing, demand in India & quality. “India is not a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback